Kriya Therapeutics KRIYA-839 (AAV insulin + glucokinase gene therapy)
Kriya Therapeutics
A one-time gene therapy that turns a person's own thigh muscle into a glucose-responsive insulin factory. A single AAV injection delivers two genes — insulin and the glucose sensor glucokinase — so the muscle makes insulin in response to blood sugar. Announced as the first-ever AAV gene-therapy trial in type 1 diabetes (the PROGRESS study); human dosing has not yet been reported.
The scorecard
In type 1 diabetic mouse and dog models a single dose gave durable glucose control, but there is no human efficacy data yet, so a real-world T1D benefit is unproven.[1]
Animal studies showed glucose-lowering lasting up to four years from one injection, fitting AAV's long expression; human durability is untested.[2]
Designed as a low-dose intramuscular AAV (a route with a relatively favorable AAV safety record), but no human safety data exist and unregulated insulin output is a theoretical hypoglycemia concern.[2]
A simple outpatient injection that does not replace cells or need immunosuppression could in principle suit broad T1D, though pre-existing AAV immunity would exclude some; the announced trial targets adults on closed-loop with HbA1c above 7%.[2]
Strong multi-species preclinical package and an announced first-in-human trial, but as of 14 July 2026 no participant has been dosed, no IND clearance has been announced, and a ClinicalTrials.gov sponsor search returns no Kriya type 1 diabetes study.[2]
Immunosuppression-free is scored here, as it is for cell replacement and encapsulation — freeing a therapy from lifelong anti-rejection drugs is the central barrier this whole pillar is trying to clear, so an approach that achieves it must be able to earn credit for it. It is scored on evidence, not intent: a platform designed to avoid immunosuppression but never yet tested at a therapeutic dose scores on what it has shown. Approaches that transplant nothing (in-vivo gene therapy, reprogramming) need no anti-rejection drugs by construction, but they still face the original autoimmune attack — that unresolved risk belongs in this score, not hidden by it.
The full picture
Most cures in development replace the islet cells that type 1 diabetes destroys. Kriya Therapeutics is trying something different: skip the cells entirely and reprogram a tissue the disease never attacks — skeletal muscle. KRIYA-839 is an adeno-associated virus (AAV) gene therapy that delivers two genes at once: human insulin, and glucokinase, an enzyme that acts as a glucose sensor. Injected into the thigh muscles during a single outpatient visit, the muscle is meant to become a standing insulin factory that releases more insulin as blood sugar rises and stays quiet when it falls, with glucokinase providing the glucose-responsiveness.
The evidence so far is preclinical. In mouse and dog models of type 1 diabetes, a single treatment lowered blood sugar durably, with effects reported to last up to four years in animals. On that strength, Kriya announced the PROGRESS study — described as the first-ever AAV gene-therapy trial in type 1 diabetes — enrolling adults already using closed-loop pumps, with a 52-week follow-up for safety and effect on insulin use.
Important caveats: as of 14 July 2026 no human has been dosed in the public record, no IND clearance has been announced, and a ClinicalTrials.gov search of Kriya's sponsored studies still returns no type 1 diabetes trial — more than half of the year in which the PROGRESS study was meant to start has now passed without a registry record appearing. Open questions include how tightly muscle-made insulin can be controlled (hypoglycemia risk), how pre-existing AAV immunity limits who can be treated, and whether animal durability carries into people. If it works, the appeal is a one-time, cell-free, immunosuppression-free shot — but that remains unproven.
Coming soon
ETA · First-in-human PROGRESS trial announced to begin in 2026; no human data yet, with any approval many years away.
- →Start the first-in-human PROGRESS Phase 1/2 trial (single intramuscular dose, 52-week follow-up) · 2026
- →Report initial human safety and C-peptide / insulin-use data · after 2026
Sources
- [1]Metabolic Disease: Gene Therapy for Diabetes — KRIYA-839 (Kriya Therapeutics pipeline) · manufacturer · 2026-01-01
- [2]Gene Therapy to Be Studied for Treating Type 1 Diabetes (PROGRESS study of KRIYA-839) · news · 2026-01-01
- [3]Treatment of diabetes and long-term survival after insulin and glucokinase gene therapy (Callejas et al., Diabetes) · peer-reviewed · 2013-05-01
- [4]855-P: Evolution of KT-A112, an AAV-Mediated Gene Therapy for the Treatment of Type 1 Diabetes · conference · 2023-01-01